About Sollis Therapeutics
Sollis Therapeutics is a clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics. Sollis’ first product is an extended release combination analgesic and anti-inflammatory drug designed for local delivery for the treatment of sciatica and other neuropathic pain syndromes.
Sollis was founded and received seed-funding from an Ohio-based organization, the Neurotechnology Innovations Translator (NIT). Sollis also received a grant from the Ohio Opioid Abuse, Prevention and Treatment Technology Initiative. The grant was awarded based upon the acknowledgement that Sollis’ first therapy, STX-015, may decrease the requirement and use of opioid analgesics to treat severe sciatica pain.